Prostate Cancer: Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 72 year old man with history of Gleason Score 4+3 =7 adenocarcinoma diagnosed by prostate biopsy after the patient was found to have an elevated PSA of 212.  Originally posted on a forum in the ASCO Connection, users now have the opportunity to claim CME, completion, or participation certificates for completing this activity.

Originally posted on a forum in the ASCO Connection, participants now have the opportunity to claim CME, completion, or participation certificates for completing this activity.

Learning Objectives

  • Evaluate the pathological and clinical prognostic features for catration resistant adenocarcinoma of the prostate
  • Analyze the potential role of ARV7 expression in circulating tumor cells in prostate cancer
  • Discuss the role of tumor molecular testing in the therapeutic management in patients with Adenocarcinoma of the prostate

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.
Important Notes
  • This course expires on July 29, 2018. Participants must complete all necessary course components by this date to receive credit.